Applications of nanoparticles in treatment and diagnosis of leukemia

Soni, Govind; Yadav, Khushwant S.

doi:10.1016/j.msec.2014.10.043

Cited by 72 publications

(37 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, NPs have the ability to circumvent the P-glycoprotein efflux pump which is present on the membranes of HIV reservoir cells as well as intestinal epithelial cells (Zhang et al, 2013). This in turn, increases the absorption as well as target the antiretroviral drug to HIV reservoir sites (Soni & Yadav, 2015).…”

Section: Introductionmentioning

confidence: 99%

Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles

2016

View full text Add to dashboard Cite

Nanoparticles (NPs) can be absorbed via M cells of Peyer's patches after oral delivery leading to passive lymphatic targeting followed by systemic drug delivery. Hence, the study was aimed to formulate PLGA NPs of lopinavir. The NPs were prepared by nanoprecipitation, optimized by 3 3 factorial design and characterized by TEM, DSC, FTIR studies and safety was assessed by MTT assay. In vivo pharmacokinetic studies were performed in rats. The NPs were discrete spherical structures having particle size of 142.1 ± 2.13 nm and entrapment of 93.03 ± 1.27%. There was absence of drug-polymer interaction. Confocal images revealed the penetration and absorption of coumarin-loaded NPs in Caco-2 cells and intestine after oral delivery. There was 3.04 folds permeability and 13.9 folds bioavailability enhancement from NPs. The NPs can be promising delivery system for antiretroviral drug by delivering the drug to lymph (major HIV reservoir site) via direct absorption through intestine before reaching systemic circulation.

show abstract

Section: Introductionmentioning

confidence: 99%

Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles

2016

View full text Add to dashboard Cite

show abstract

“…It is not necessary that the blood tests confirm that the person is having leukemia and it's most common in the early stage. In some situations a lymph node biopsy is too necessary to diagnose certain types of leukemia (Soni et al, 2015). MRI, X-ray or ultrasound also use to check the hurdles which are arise due to leukemia.…”

Section: Gene Therapy For Leukemia Treatmentmentioning

confidence: 99%

Gene therapy as advanced technology for the treatment of Leukemia: CAR-T therapy

Tripathi¹,

Singh²

2018

Asian J Pharm Pharmacol

View full text Add to dashboard Cite

“…Due to the lack of specific anticancer therapies, common treatments of leukemia lead to severe side effects. Nonspecific anticancer drugs result in inhibition of normal cell growth and thereby their necrosis . The type of leukemia and the patient's general health and age are the main factors in finding the appropriate treatment .…”

Section: Introductionmentioning

confidence: 99%

“…Nonspecific anticancer drugs result in inhibition of normal cell growth and thereby their necrosis. 11 The type of leukemia and the patient's general health and age are the main factors in finding the appropriate treatment. 12 Drug resistance is an additional problem, which stands in the way of leukemia treatment.…”

mentioning

confidence: 99%

Melatonin: A promising agent targeting leukemia

Shafabakhsh

Mirzaei

Asemi

2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Leukemia or cancer of blood is a well‐known cancer, which affects a range of people from newborns to the very old. It is a public health problem throughout the world. By way of treatment, due to the lack of specific anticancer therapies, common treatments of leukemia lead to severe side effects. Nonspecific anticancer drugs result in inhibition of normal cell growth and thereby their necrosis. Moreover, drug resistance is an additional problem, which stands in the way of leukemia treatment. Thus, finding new treatments for leukemia is essential. Melatonin, as a natural product, has been shown to be effective in a wide variety of diseases such as coronary heart disease, schizophrenia, chronic pain, and Alzheimer's disease. In addition, melatonin levels have been observed to be altered in different cancers, such as breast cancer, colorectal cancer endometrial cancer, and hematopoetical cancers. Anticancer features of melatonin such as pro‐oxidation, apoptosis induction, antiangiogenesis property and metastasis and invasion inhibition suggest that this natural compound can be used as a potential agent in novel therapeutic strategies for cancers. Also, it has been reported that melatonin has positive and protective effects on different physiological reactions and in normal bone marrow cells suggesting effectiveness in leukemia therapy. Thus, the aim of our paper was to depict and summarize the main molecular targets of melatonin on leukemia models.

show abstract

Applications of nanoparticles in treatment and diagnosis of leukemia

Cited by 72 publications

References 63 publications

Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles

Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles

Gene therapy as advanced technology for the treatment of Leukemia: CAR-T therapy

Melatonin: A promising agent targeting leukemia

Contact Info

Product

Resources

About